Description
Human Recombinant BLMH is available at Gentaur for Next week delivery.
Shields normal and malignant cells from antitumor drug BLM
Biomolecule/Target:
Alternates names: Bleomycin hydrolase, BH, BMH.
Synonyms: Human Recombinant BLMH
Background Information: BLMH is affiliate to the papain superfamily of the cysteine protease and the peptidase C1 family. BLMH is a cytoplasmic cysteine peptidase usually found as a homohexamer. The standard physiological role of BLMH has not been determined, but it shields normal and malignant cells from the glycopeptide antitumor drug BLM. BLMH catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxyamide bond of its B-aminoalaninamide moiety and in addition demonstrates general aminopeptidase activity.
Reconstitution Instructions: N/A
NCBI Gene Symbol: BLMH
Gene ID: 642
NCBI Accession: Q13867
Additional Information
Size: |
100 μg |
Country of Manufacturing Origin: |
USA |
Country of Animal Origin: |
USA |
Gene Source: |
Human |
Recombinant: |
Yes |
Source: |
E. Coli |
Purity by SDS-PAGE: |
≥90% |
Assay: |
SDS-PAGE |
Purity: |
N/A |
Assay 2: |
N/A |
Endotoxin Level: |
N/A |
Activity (Specifications/test method): |
N/A |
Biological activity: |
Specific activity: > 1,000 pmole/min/µg. Measured by the hydrolysis of Met-AMC at pH 7.5, at 37°C. |
Results: |
>1,000 pmole/min/µg |
Molecular Weight: |
54.7 kDa (475 aa, 1-455 aa + NT His Tag) |
Storage Temperature: |
-20°C |
Shelf Life: |
12 months |
Concentration: |
1 mg/ml |
Appearance: |
Liquid |
Handling: |
Centrifuge the vial prior to opening. |